Free guide
Ozempic vs Wegovy vs Zepbound: Price Comparison
Ozempic (semaglutide) is FDA-approved for type 2 diabetes; Wegovy is FDA-approved semaglutide for chronic weight management; Zepbound is FDA-approved tirzepatide for chronic weight management. Self-pay prices differ by program, dose, and access channel, and are not interchangeable prescriptions.

- 1
Read
Start with the short answer.
- 2
Prepare
Take a question from the research.
- 3
Speak
Bring it to a physician.

For your visit
Speak to a physician
Feel Ready visits are not open yet. These questions are ready for a physician you already see.
Written by Feel Ready Editorial Team
Last updated November 2026
Brand names are not interchangeable
Ozempic, Wegovy, and Zepbound contain different approved indications and dosing schedules even when they share an active ingredient class. A clinician chooses based on diagnosis, benefits, risks, and coverage—not on which name appears in an ad.
Compounded semaglutide or tirzepatide should not be marketed to consumers as Ozempic or Zepbound.
Advertised self-pay price snapshots
As of November 7, 2026, manufacturer-linked self-pay programs have publicly listed Wegovy near $199 for introductory periods then higher ongoing monthly rates, Ozempic self-pay often in a similar headline range depending on dose, and Zepbound often advertised from about $299 upward. Lilly and Novo programs change terms frequently.
Insurance, coupons, and employer benefits may differ from self-pay rates.
Why this matters for online care shoppers
Telehealth platforms increasingly route patients to FDA-approved medicines at manufacturer self-pay prices rather than compounded copies. Compare total care cost—consult access, follow-up, and fulfillment—not only the medicine line item.
Compounded semaglutide and tirzepatide are not the same products as FDA-approved Ozempic, Wegovy, or Zepbound. Compounding availability depends on patient-specific clinical need and applicable federal and state rules. The FDA has tightened routine compounding of copies now that approved products are commercially available.
| Medicine | Active ingredient | Typical FDA-approved use | Self-pay notes (2026 ads) |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | Not a weight-brand label; price varies by dose |
| Wegovy | Semaglutide | Chronic weight management | Intro offers often ~$199, then higher |
| Zepbound | Tirzepatide | Chronic weight management | Often from ~$299 with conditions |
Sources
What to ask a physician
These checked public sources are the background for this guide. They do not diagnose you, and they do not tell a physician what to prescribe.
Related guides
Curious about what comes next?
Join the waitlist. When clinician-guided care opens in your state, Feel Ready will contact you about a private consultation. There is no treatment or payment today.
Join the Waitlist